Investigators at Translational Research Institute Report Findings in Gene Therapy (Aav-based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances In Age-related Macular Degeneration and Diabetic Retinopathy Therapies).

A report from the Translational Research Institute in Brisbane, Australia discusses the use of adeno-associated virus (AAV) as a vector for ocular gene delivery in the treatment of age-related macular degeneration (AMD) and diabetic retinopathy (DR). Current treatments for these vascular diseases are burdensome and have limitations, so there is a need for long-lasting alternatives with improved safety and efficacy. The report explores various strategies using AAV-mediated gene delivery, including engineered capsids, targeted expression, gene silencing, and editing. The report provides an overview of preclinical efficacy studies and the latest data from clinical trials for both diseases. [Extracted from the article]

Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)